Pharmexa A/S
π©π°Denmark
- Country
- π©π°Denmark
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.pharmexa.com
A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2008-12-18
- Lead Sponsor
- Pharmexa A/S
- Target Recruit Count
- 41
- Registration Number
- NCT00444782
- Locations
- πͺπΈ
Jordi Bruix, Barcelona, Spain
π«π·Michel Beaugrand, Bondy, France
π©πͺTim F. Greten, Hannover, Germany
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Phase 3
Terminated
- Conditions
- Advanced Unresectable Pancreatic Cancer
- Interventions
- Biological: GV1001
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2008-05-19
- Lead Sponsor
- Pharmexa A/S
- Target Recruit Count
- 360
- Registration Number
- NCT00358566
- Locations
- πΊπΈ
The Center for Hematology-Oncology, Boca Raton, Florida, United States
πΊπΈOncology Consultants, PA, Houston, Texas, United States
πΊπΈPalm Beach Cancer Institute, West Palm Beach, Florida, United States
Β© Copyright 2025. All Rights Reserved by MedPath